VBL Therapeutics to Present at the UBS Global Life Sciences Conference

Published: Sep 13, 2011

TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that Dror Harats, M.D., chief executive officer of VBL, is scheduled to present at the UBS Global Life Sciences Conference on Tuesday, September 20, 2011 at 10:30 a.m. EDT at the Grand Hyatt New York.

Back to news